OutLAST Regulators are designed proteins that reprogram critical T cell signaling pathways to enhance functional persistence and are implemented as compact genetic modules compatible with standard viral vectors and cell therapy manufacturing processes, creating a powerful platform for programming new functions into enhanced cell and gene therapies.
Abstract
The efficacy of engineered T cell therapies in solid tumors remains limited by T cell dysfunction, driven by complex processes that cannot be easily manipulated via genetic knockouts or overexpression of individual genes. Protein design can create new biological functions that can rewire these consequential cell fate decisions. Here, we introduce OUTLAST Regulators, designed proteins that reprogram critical T cell signaling pathways to enhance functional persistence. These proteins are capable of regulating diverse groups of proteins such as the NR4A family of pro-exhaustion transcription factors, E3 ligases Cbl-b and c-Cbl, and SOCS family proteins. Our designs markedly improve CAR-T and TCR-T performance in vitro and in vivo in stringent solid tumor preclinical models. OUTLAST Regulators are implemented as compact genetic modules compatible with standard viral vectors and cell therapy manufacturing processes, creating a powerful platform for programming new functions into enhanced cell and gene therapies.
It is demonstrated that reconfiguring existing protein domains may uncover non-evolved genes that program therapeutically relevant cell states that program therapeutically relevant cell states.
Oliver Takacsi-Nagy, Sivakanthan Kasinathan, Austin Hartman et al.· Cell· 0 citations
This work fuses tamoxifen-responsive ER ligand-binding domains to CARs to generate ligand-inducible ON-switch CARs whose stability, signaling, and effector functions are precisely controlled by 4-hydroxytamoxifen.
Erik Rihtar, Tina Fink, Monika Belak et al.· bioRxiv· 0 citations
Key challenges related to the biodistribution, activation, and persistence of modified T cells are highlighted, with an emphasis on the potential of these strategies for treating not only blood cancers but also solid tumors, autoimmune diseases, and beyond.
Jens B. Simonsen, Viktor T. Lemgart, J. Kulkarni et al.· Advanced Drug Delivery Revie...· 1 citation
This review underscores that optimizing T-cell therapy requires treating manufacturing not as a logistical necessity but as a controllable biological intervention, and a mechanistic understanding of how processing decisions program cellular behavior will enable the rational design of more potent, durable, and scalable...
Nikolai Przybylski, Qing-He Zeng, Xiao Huang· Advances in Pharmacology· 0 citations
In general, CRISPR/Cas9-based engineering is a promising way of developing the next generation of precision cancer immunotherapy and is likely to be improved further in future through advancements in genome editing technology, delivery methods, and synthetic biology.
Meng-Ying Liu· International Journal of Bio...· 0 citations